NASDAQ:RNAZ TransCode Therapeutics Q3 2025 Earnings Report $1.76 +0.11 (+6.67%) As of 09/21/2026 03:59 PM Eastern ProfileEarnings HistoryForecast TransCode Therapeutics EPS ResultsActual EPS-$5.49Consensus EPS -$9.24Beat/MissBeat by +$3.75One Year Ago EPSN/ATransCode Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATransCode Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time4:00PM ETUpcoming EarningsTransCode Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) TransCode Therapeutics Earnings HeadlinesTransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeptember 16, 2026 | seekingalpha.comJoin Today’s Live Investor Webinar with TransCode TherapeuticsSeptember 16, 2026 | usatoday.com“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown, founder of Brownstone Research, calls it M.A.G.I. Venture capitalist Jason Calacanis, who turned $100,000 into $100 million from Uber's IPO, previewed the technology privately and called it the best selling product he has ever seen. | Brownstone Research (Ad)TransCode Therapeutics Announces Leadership TransitionSeptember 10, 2026 | prnewswire.comJoin TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic CancerSeptember 3, 2026 | usatoday.comTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisAugust 31, 2026 | prnewswire.comSee More TransCode Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TransCode Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your email. Email Address About TransCode TherapeuticsTransCode Therapeutics (NASDAQ:RNAZ), Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for the treatment of metastatic cancer. The company’s research is centered on therapies designed to target biological mechanisms involved in cancer spread while helping deliver therapeutic RNA to tumor sites. TransCode’s lead investigational product is TTX-MC138, an RNA therapeutic intended to inhibit microRNA-10b, a molecule associated with the development and progression of metastatic disease. The candidate uses the company’s TTX nanoparticle delivery platform, which is designed to transport therapeutic payloads to tumors. Based in Boston, Massachusetts, TransCode conducts research and clinical development activities primarily in the United States. Its programs remain investigational and are subject to clinical testing and regulatory review; the company’s therapies are not yet approved for general commercial use.View TransCode Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
